Department of Vascular and Endovascular Surgery-University of Cologne, Faculty of Medicine and University Hospital Cologne, Germany.
Vasa. 2023 May;52(3):175-185. doi: 10.1024/0301-1526/a001061. Epub 2023 Mar 9.
The total endovascular repair of the aortic arch is becoming more and more an acceptable alternative to the open repair in selected patients. The aim of the present study is to perform a meta-analysis of the available data on the outcomes of the various endovascular techniques used to treat the pathologies in this challenging anatomical area. An extensive electronic search in PubMed/MEDLINE, Science Direct Databases, and the Cochrane Library was conducted. All papers published up to January 2022 on the endovascular techniques in the aortic arch (chimney-thoracic endovascular aortic repair (ChTEVAR), fenestrated/branched grafts as custom made devices (CMD) and surgeon modified TEVAR (SM TEVAR) providing information about at least one of the essential outcomes defined in the inclusion criteria. Out of the 5078 studies found through the search in the databases and registers, 26 studies with a total number of patients of 2327 with 3497 target vessels were included in the analysis. The studies reported a high technical success rate with an estimated proportion of 95.8% (95% CI, 93-97.6%). Moreover, the pooled estimation of the early type Ia/III endoleak was 8.1% (95% CI, 5.4-12.1%). The pooled mortality was 4.6% (95 CI, 3.2-6.6%) with a significant heterogeneity and the stroke had an estimated proportion (major and minor combined) of 4.8% (95% CI, 3.5-6.6%). A meta-regression analysis showed no significant variation between the groups in mortality (P=.324) showed however a significant difference between the therapeutic methods regarding stroke P<.001 (lower rate in ChTEVAR and SM vs. CMD). The present meta-analysis could demonstrate good short- and long-term outcomes of the multiple total endovascular repair methods used in the aortic arch.
全腔内主动脉弓修复术在某些特定患者中,正越来越成为一种可接受的替代开放修复的方法。本研究旨在对各种腔内技术治疗该挑战性解剖区域病变的可用数据进行荟萃分析。
我们在 PubMed/MEDLINE、Science Direct 数据库和 Cochrane 图书馆进行了广泛的电子检索。检索截止至 2022 年 1 月,所有关于主动脉弓腔内技术(烟囱-胸主动脉腔内修复术(ChTEVAR)、定制分支型覆膜支架(CMD)和外科改良 TEVAR(SM TEVAR))的论文都包含至少一个纳入标准中定义的重要结果的信息。
在数据库和登记处的搜索中发现了 5078 项研究,其中 26 项研究共纳入了 2327 例患者和 3497 个靶血管。研究报道了较高的技术成功率,估计比例为 95.8%(95%CI,93-97.6%)。此外,早期 I 型/III 型内漏的汇总估计为 8.1%(95%CI,5.4-12.1%)。汇总死亡率为 4.6%(95%CI,3.2-6.6%),异质性显著,卒中的估计比例(主要和次要卒中合并)为 4.8%(95%CI,3.5-6.6%)。meta 回归分析显示,死亡率在各组间无显著差异(P=.324),但治疗方法间的卒中存在显著差异(P<.001,ChTEVAR 和 SM 组低于 CMD 组)。
本荟萃分析可以证明,在主动脉弓中使用的多种全腔内修复方法具有良好的短期和长期效果。